A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients.
about
Arginine deprivation therapy for malignant melanomaProgress in systemic therapy of advanced hepatocellular carcinomaTargeting amino acid metabolism in cancer growth and anti-tumor immune responseComponents of cancer metabolism and therapeutic interventionsAmino acid deprivation using enzymes as a targeted therapy for cancer and viral infectionsSystemic therapy for advanced hepatocellular carcinoma: an update.Single amino acid arginine deprivation triggers prosurvival autophagic response in ovarian carcinoma SKOV3The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.Novel systemic therapy against malignant pleural mesothelioma.Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells.Arginine deprivation affects glioblastoma cell adhesion, invasiveness and actin cytoskeleton organization by impairment of β-actin arginylation.Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy.Investigational cancer drugs targeting cell metabolism in clinical development.Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors.Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetasePegylated arginine deiminase downregulates colitis in murine models.Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine.Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy.Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.Nitric oxide is a positive regulator of the Warburg effect in ovarian cancer cellsHemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies.Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas.Targeting nitric oxide signaling with nNOS inhibitors as a novel strategy for the therapy and prevention of human melanoma.18F-AFETP, 18F-FET, and 18F-FDG imaging of mouse DBT gliomas.Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas.Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges.Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights.Treating advanced hepatocellular carcinoma: How to get out of first gear.The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials.Chemotherapy for hepatocellular carcinoma: The present and the future.Drug-induced amino acid deprivation as strategy for cancer therapy.Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.Arginine deiminase: recent advances in discovery, crystal structure, and protein engineering for improved properties as an anti-tumor drug.Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer CellsArginine dependence of tumor cells: targeting a chink in cancer's armor.Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium.Advanced Hepatocellular Cancer: the Current State of Future Research.
P2860
Q24634269-33C55FDF-435E-4E21-ADE3-E47CAFC0E907Q26740217-240DA276-5F21-4BEA-A4B2-6003403EE981Q26775425-48738A89-3423-4117-AEFC-4D06C2E3FB1BQ26823746-368429D2-5FF5-49A7-87A1-3D8222302E4FQ30040775-2BD52E12-DC43-4D54-8C60-AD7D3C00F6B3Q33593213-0EA85D66-ED04-4106-A2A8-F995143EA446Q33759388-C5D644E6-99F0-41EC-9C90-64783851F503Q33838601-09E4A6DA-62AC-42B0-89B6-343BA5D23A8DQ33890499-0197CF71-76C8-4A29-B1C8-CBE50E1D2BC5Q34213639-37252FE9-AFCF-45C7-A01D-A5D9474C9AFDQ34497105-E064FC01-E70A-47AC-BB3E-F5B267DAD199Q34807813-52DD3D0D-D3F3-4CB7-AE75-CEAC75818634Q35233239-3BC864AA-A05C-420A-8AD9-279513BD05B9Q35535519-44658219-549F-4D36-8E94-4453A3AA163DQ35615701-2ECA9D14-C798-4332-9BD4-3F2862DB907CQ35674875-14F8823F-AC54-435A-B7F3-BD0054D02F2EQ35682009-E27ADE24-C1D1-403B-869C-5477EF4B0F46Q35725419-C8A4BCC0-26CA-4DA3-A4CD-2EAD8A9C763AQ35781589-0550AD0A-65BB-4CE5-9601-03DF3A1CB153Q35803555-061B8749-BB75-451E-8D32-7A19307ECC47Q36121733-52CFE742-3072-4AB4-A605-217D82B17BE4Q36179641-DC2446B0-0720-41CF-BED0-3B2772252F4AQ36644408-1939B27A-6019-4B52-A1B2-F3F84AFAF223Q36873800-76DCDE58-5F39-4720-AD71-0386296AC723Q36991145-3DF711F3-2A61-4FD2-8160-3184CFA1612AQ37155873-A60525A2-132D-4C77-8CEC-52DC391AEB61Q37339881-22E3C5DF-F8D4-4EE2-BB57-BC9A9176D6C7Q37465815-F4D14FB4-BAE3-4344-A049-1C13A22756B6Q38181070-0BB6934F-8F56-4BBB-9676-98A92AE97A16Q38201707-85B2F43F-FA3B-47A2-BCA0-6418AB6751F4Q38217737-6A27626C-6B1E-469F-92CA-FFBAF2401EF2Q38223301-746A7305-4A70-4AC8-965F-CD714577023DQ38639762-2ACD8068-268E-453F-A919-ECEBBC75EFBCQ38657061-98477ACA-4B73-44FF-BDF3-C6190CD993ADQ38733577-47DFB376-2EF9-4C2B-B3F2-40C01CF8B84AQ38777479-F9ED3195-8160-4D29-B50C-DB1E38ED9A13Q38814004-93E27374-C2CE-4B61-9798-76B6D76A1309Q38816145-A6CF6142-A0CD-4302-8611-F99EF463597BQ38824017-633D4AC9-CE69-4120-8B91-51E01D75F9D2Q38848537-01D65B7A-A513-4314-9C4E-67B807273FD1
P2860
A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A randomised phase II study of ...... tocellular carcinoma patients.
@ast
A randomised phase II study of ...... tocellular carcinoma patients.
@en
A randomised phase II study of pegylated arginine deiminase
@nl
type
label
A randomised phase II study of ...... tocellular carcinoma patients.
@ast
A randomised phase II study of ...... tocellular carcinoma patients.
@en
A randomised phase II study of pegylated arginine deiminase
@nl
prefLabel
A randomised phase II study of ...... tocellular carcinoma patients.
@ast
A randomised phase II study of ...... tocellular carcinoma patients.
@en
A randomised phase II study of pegylated arginine deiminase
@nl
P2093
P2860
P356
P1476
A randomised phase II study of ...... tocellular carcinoma patients.
@en
P2093
J A Thomson
J Wang-Peng
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605856
P407
P577
2010-08-31T00:00:00Z
P5875
P6179
1027168571